CLINICAL_TRIALS
trial_result
· 2015-08-14
Clinical Trial Update: Study of Lanreotide in Non Metastatic Castration-resistant Prostate Cancer Patients [Phase 3]
Summary
Phase 3 trial of lanreotide in non-metastatic castration-resistant prostate cancer was terminated; results posted in 2015.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Ipsen | Conditions: Prostate Cancer | Phase 3 | Status: TERMINATED | Results posted: 2015-08-14